IMvigor210, trial summary    PDF trial summary

A randomised clinical trial investigating the effect of atezolizumab versus nil in Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. Cohort 2 will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen

        Z

NCT02951767    Lancet 2017;389:67-76  
1st line 2nd line



Studied treatment Atezolizumab
Control treatment single arm study



Patients Cohort 1 will consist of participants who are treatment-naïve and ineligible for cisplatin-containing chemotherapy. Cohort 2 will contain participants who have progressed during or following a prior platinum-based chemotherapy regimen
Group sizes-9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design Single-arm study

phase 2



EndpointX1N1X0N0TE95% CI PFS - -9 - -9 no data ORR - -9 - -9 no data OS - -9 - -9 no data CR - -9 - -9 no data0,22,01,0

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67-76     [PMID: 27939400]   link to pdf   add to Mendeley  

ClinicalTrial.gov record NCT02951767



Registering number NCT02951767 (see trial on clinicaltrials.gov)
Code Name